[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369949-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369949-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","novel-immunohistochemical-assay-utilizing-the-insm1-sp493-antibody-demonstrates-high-specificity-and-sensitivity-in-detecting-primary-neuroendocrine-lung-neoplasms","Novel immunohistochemical assay utilizing the INSM1 (SP493) antibody demonstrates high specificity and sensitivity in detecting primary neuroendocrine lung neoplasms","","Immunohistochemistry-based identification of primary neuroendocrine lung neoplasms relies on neuroendocrine marker expression, including synaptophysin, chromogranin A, and CD56. A newly developed assay using the INSM1 (SP493) antibody was evaluated for diagnostic sensitivity, specificity, and accuracy, and compared with assays using established neuroendocrine markers. Using tissue microarrays containing 391 lung neoplasms, the INSM1 (SP493) assay achieved high performance metrics, supporting its use as a reliable diagnostic marker.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/novel-immunohistochemical-assay-utilizing-the-insm1-sp493-antibody-demonstrates-high-specificity-and-sensitivity-in-detecting-primary-neuroendocrine-lung-neoplasms/369949/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/novel-immunohistochemical-assay-utilizing-the-insm1-sp493-antibody-demonstrates-high-specificity-and-sensitivity-in-detecting-primary-neuroendocrine-lung-neoplasms/369949.png","ImageObject",300,407,{"name":42,"@type":43},"Guten tag","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of the study?","Question",{"text":63,"@type":64},"To assess the diagnostic sensitivity and specificity of a new INSM1 (SP493) immunohistochemical assay for detecting primary neuroendocrine lung neoplasms and to compare it with currently used markers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the INSM1 (SP493) assay evaluated?",{"text":68,"@type":64},"Tissue microarrays containing 391 lung neoplasms were stained with INSM1 (SP493) and several comparator antibodies, and sensitivity, specificity, and accuracy were calculated for each biomarker.",{"name":70,"@type":61,"acceptedAnswer":71},"What diagnostic performance did INSM1 (SP493) achieve?",{"text":72,"@type":64},"For neuroendocrine-differentiated primary lung neoplasms, the INSM1 (SP493) assay showed a sensitivity of 96.8% and a specificity of 92.3%.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369949,1790556561,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118,"preview_page_count":33,"preview_urls":145},687212321768,"https://ap-avatar.wpscdn.com/avatar/a0010bdbe886d2fe77?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789897067658708522","Dvorak et al. Diagnostic Pathology (2025) 20:118 [https://doi.org/10.1186/s13000-025-01724-0](https://doi.org/10.1186/s13000-025-01724-0)  \nDiagnostic Pathology  \nRESEARCH Open Access  \nNovel immunohistochemical assay utilizing the INSM1 (SP493) antibody demonstrates high specificity and sensitivity in detecting primary neuroendocrine lung neoplasms  \nKaterina Dvorak 1*, Alexander Gomez 1 and Rafael Sainz 1  \nAbstract  \nIntroduction About 15–20% of lung neoplasms are of neuroendocrine origin. In addition to evaluation of morphological features, these neoplasms can be identified by immunohistochemistry (IHC) using antibodies against neuroendocrine markers such as synaptophysin, chromogranin A, and neural cell adhesion molecule,  \nCD56 . Recent studies have shown that insulinoma-associated protein 1 (INSM1) is increasingly used as a diagnostic marker for neoplasms of neuroendocrine origin, as it is highly sensitive and specific. The primary focus of this  \nstudy was to evaluate the sensitivity and specificity of a recently developed assay that uses a new INSM1 (SP493) antibody for detecting primary neuroendocrine lung neoplasms and to compare this IHC assay with currently used neuroendocrine markers.  \nMethod Tissue microarrays containing 391 lung neoplasms were stained with INSM1 (SP493) antibody, INSM1 (MRQ-70) antibody, CONFIRM anti-Synaptophysin (SP11) antibody, anti-Chromogranin A (LK2H10) antibody, and CD56 (MRQ-42) antibody on BenchMark ULTRA instruments using OptiView IHC DAB Detection Kit or ultraView Universal DAB Detection Kit using manufacturer’s recommended protocols. Sensitivity, specificity, and accuracy were calculated for each biomarker.  \nResults The sensitivity and specificity of the new assay using INSM1 (SP493) antibody for detecting primary lung neoplasms with neuroendocrine differentiation were 96. 8% and 92. 3%, respectively. Comparable results were seen for the lung neoplastic cases stained with INSM1 (MRQ-70) antibody, yielding a sensitivity of 94 . 9% and specificity of 94. 1% . In contrast, the anti-Chromogranin A (LK2H10) antibody and CD56 (MRQ-42) antibody showed considerably lower sensitivities. The sensitivity was 78 . 7% for the anti-Chromogranin A (LK2H10) antibody and 85.4% for the CD56 (MRQ-42) antibody. However, the specificities of anti-Chromogranin A (LK2H10) antibody and CD56 (MRQ- 42) antibody were comparable with the specificity ofthe INSM1 (SP493) antibody [91 . 7% for anti-Chromogranin A (LK2H10) antibody, 90.4% for CD56 (MRQ-42) antibody] . The performance of the anti-Synaptophysin (SP11) antibody was suboptimal, with a sensitivity of 82 . 9% and a specificity of 87 . 6% .  \n*Correspondence:  \nKaterina Dvorak [katerina.dvorak@roche.com](katerina.dvorak@roche.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nDvorak et al. Diagnostic Pathology (2025) 20:118 Page 2 of 8  \nConclusions Overall, our","cbCaiv575dJKKPWV","https://ap.wps.com/l/cbCaiv575dJKKPWV","pdf",1516892,"English","# Abstract\n# Introduction\n# Method\n# Results\n# Conclusions\n# Keywords","[{\"question\":\"What was the main goal of the study?\",\"answer\":\"To assess the diagnostic sensitivity and specificity of a new INSM1 (SP493) immunohistochemical assay for detecting primary neuroendocrine lung neoplasms and to compare it with currently used markers.\"},{\"question\":\"How was the INSM1 (SP493) assay evaluated?\",\"answer\":\"Tissue microarrays containing 391 lung neoplasms were stained with INSM1 (SP493) and several comparator antibodies, and sensitivity, specificity, and accuracy were calculated for each biomarker.\"},{\"question\":\"What diagnostic performance did INSM1 (SP493) achieve?\",\"answer\":\"For neuroendocrine-differentiated primary lung neoplasms, the INSM1 (SP493) assay showed a sensitivity of 96.8% and a specificity of 92.3%.\"}]","Novel immunohistochemical assay utilizing the INSM1 (SP493) antibody demonstrates high specificity and sensitivity in detecting primary neuroendocrine lung neoplasms | PDF",1790185360,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/194afa9c213a21702802c1804124aeed.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0df7237df7b8e96d09caff5d1e01a057.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b13fc991242175c267b63e9fa44bfef.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d1ddab300c5691d29b1d5013ec734413.webp",980,1306]